LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Metastasis Workup for Alveolar Paratesticular Rhabdomyosarcoma: 18F-FDG PET/CT Versus 99mTc-FAPI-46 SPECT/CT.

We present a 19-year-old man with alveolar paratesticular rhabdomyosarcoma (RMS) who underwent restaging with both 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/ computed tomography (CT) and 99mTc-fibroblast activation protein inhibitor (FAPI)-46 single-photon… Click to show full abstract

We present a 19-year-old man with alveolar paratesticular rhabdomyosarcoma (RMS) who underwent restaging with both 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/ computed tomography (CT) and 99mTc-fibroblast activation protein inhibitor (FAPI)-46 single-photon emission computed tomography (SPECT)/CT after the initial surgery. Despite normal retroperitoneal lymph nodes on CT, 18F-FDG PET/CT revealed a recurrent mass in the spermatic cord stump and an inguinal lymph node, which was not detected by 99mTc-FAPI SPECT/CT. Our case highlights the superior efficacy of 18F-FDG PET/CT compared with 99mTc-FAPI SPECT/CT in restaging paratesticular RMS, consistent with previous studies demonstrating the utility of 18F-FDG PET/CT in the initial staging of RMS. This report underscores the importance of selecting the optimal imaging modality for accurate disease assessment and management in this aggressive and rare tumor subtype.

Keywords: 18f fdg; fdg pet; fapi spect; 99mtc fapi

Journal Title: Clinical nuclear medicine
Year Published: 2025

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.